AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35963986
Drug: Bosutinib 400
RxNorm normalized name: bosutinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 400 mg once daily
Trial: 34544463
Drug: Solnatide (AP301),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solnatide (AP301), administered twice daily for 7 days
Trial: 34544463
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered twice daily for 7 days
Trial: 35189571
Drug: Tongue isometric
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongue isometric pressure exercises using the Iowa Oral Performance Instrument with an increasing scheme of 5% load weekly and traditional tongue therapy for 8 weeks
Trial: 34255938
Drug: Acarbose/Metformin Fixed-Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose/Metformin Fixed-Dose Combination (50 mg/500 mg)
Trial: 34255938
Drug: Loose combination
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose combination of individual components (Acarbose and Metformin)
Trial: 34644419
Drug: Lidocaine 10%
RxNorm normalized name: LIDOCAINE 10% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 10% spray (50 mg)
Trial: 33836807
Drug: Yijinjing exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yijinjing exercise intervention combined with routine rehabilitation therapy (40 min/session, 3 sessions/week for 12 weeks)
Trial: 33836807
Drug: Routine rehabilitation
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine rehabilitation therapies (occupational therapy, physical therapy, acupuncture therapy, health education) 5 times a week for 3 months
Trial: 35552197
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (2x10^9 cfu/day for 30 days)
Trial: 32027620
Drug: Multiple courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple courses of NK cell infusion
Trial: 32027620
Drug: Single course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single course of NK cell infusion
Trial: 35794080
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of afatinib dimaleate (40 mg)
Trial: 35794080
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of afatinib dimaleate (40 mg)
Trial: 33515500
Drug: Maintenance intravenous
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance intravenous gemcitabine (1250 mg/m2 on days 1 and 8, in cycles of 21 days) plus supportive care
Trial: 33420185
Drug: HYAJOINT Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYAJOINT Plus (3 ml, 20 mg/ml) followed by PRP (3 ml)
Trial: 33420185
Drug: PRP (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP (3 ml)
Trial: 32553394
Drug: Continuing unilateral
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing unilateral ECT with antidepressants
Trial: 35719197
Drug: Cooling gel
RxNorm normalized name: Cooling Gel
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling gel pad application for 20 minutes duration once a day (n = 20)
Trial: 35719197
Drug: Diclofenac gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac gel application 4 times a day (n = 20)
Trial: 35997582
Drug: 9-valent HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent HPV vaccine (9vHPV)
Trial: 34450552
Drug: idd epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC)
Trial: 34450552
Drug: Leucocyte nadir-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by tailored and dose-dense docetaxel (dtD) (dtEC-dtD)
Trial: 35760910
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg daily
Trial: 34895483
Drug: Adrecizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrecizumab (8 mg/kg bodyweight)
Trial: 32740502
Drug: 3.0 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 µg/kg IND
Trial: 32740502
Drug: 3.5 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 µg/kg IND
Trial: 33742520
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K (menadiol diphosphate 5 mg, thrice weekly)
Trial: 32421762
Drug: Ivermectin mass
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin mass drug administration (MDA) for scabies
Trial: 33859155
Drug: Immediate-Release Tacrolimus
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-Release Tacrolimus (IR-Tac)
Trial: 32000711
Drug: Icotinib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib (125 mg, thrice a day)
Trial: 32000711
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg, once a day)
Trial: 35210069
Drug: Specialized yoga
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized yoga training program in addition to current guideline‐based therapy
Trial: 35210069
Drug: Current guideline‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current guideline‐based therapy alone
Trial: 32781104
Drug: Pembrolizumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab with radiation therapy (pembroRT)
Trial: 34171789
Drug: BGF 320/18/9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF 320/18/9.6 μg
Trial: 34171789
Drug: BGF 160/18/9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF 160/18/9.6 μg
Trial: 34171789
Drug: GFF 18/9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF 18/9.6 μg
Trial: 34171789
Drug: BFF 320/9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFF 320/9.6 μg
Trial: 33985595
Drug: Multi-donor FMT
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-donor FMT (capsules containing the fecal microbiota of four sex-matched lean donors)
Trial: 33985595
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline capsules)
Trial: 33507721
Drug: hCG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG plus GnRH agonist (group B)
Trial: 32851885
Drug: OS nomogram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OS nomogram incorporating age, race, histologic grade, AJCC stage, metastasis, surgery, chemotherapy, and tumor size.
Trial: 33214244
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg emixustat
Trial: 33214244
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg emixustat
Trial: 33214244
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg emixustat
Trial: 32480307
Drug: Prolonged-release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release melatonin (PRM) 2 mg for 4 weeks
Trial: 32926814
Drug: Rifabutin-based triple
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin-based triple therapy (RHB-105)
Trial: 32926814
Drug: Amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin + omeprazole
Trial: 36244398
Drug: Bemarituzumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemarituzumab (15 mg/kg bodyweight) plus mFOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus followed by 2400 mg/m2 over 46 hours)
Trial: 36244398
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus mFOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus followed by 2400 mg/m2 over 46 hours)
Trial: 35958677
Drug: Pharmacotherapeutic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapeutic treatment (group P)
Trial: 32578279
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (SC-t) 600mg every 3 weeks for 4 cycles
Trial: 32578279
Drug: Intravenous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trastuzumab (IV-t)
Trial: 32578279
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab with single injection device (SID)
Trial: 35881908
Drug: ACEI/ARB continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ARB continued in patients with eGFR < 45 mL/min
Trial: 35881908
Drug: Without ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Without ACEI/ARB in patients with eGFR < 45 mL/min
Trial: 35881908
Drug: ACEI/ARB continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ARB continued in patients with eGFR ≥ 45 mL/min
Trial: 35881908
Drug: Without ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Without ACEI/ARB in patients with eGFR ≥ 45 mL/min
Trial: 35105604
Drug: Structured prehabilitation
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured prehabilitation exercise intervention during neoadjuvant chemotherapy
Trial: 35748757
Drug: External concurrent
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External concurrent occipital and trigeminal neurostimulation
Trial: 33618977
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable MM lens 1
Trial: 33618977
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable MM lens 2
Trial: 32867053
Drug: LL‐37 neutralizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LL‐37 neutralizing antibody
Trial: 35345925
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (Zn tablets 20 mg/day)
Trial: 32017677
Drug: Immediate vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate vaccination with rVSVΔ-ZEBOV-GP Ebola vaccine
Trial: 32017677
Drug: Higher risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher risk for vaccine viremia (conception before or <14 days after vaccination)
Trial: 32017677
Drug: Lower risk
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower risk for vaccine viremia (conception >15 days after vaccination)
Trial: 32297653
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml ropivacaine 0.75%
Trial: 33827915
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) beyond 6.5 hours
Trial: 33827915
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) within 6.5 hours
Trial: 32053101
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg generic sofosbuvir in fasted state
Trial: 32053101
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg generic sofosbuvir in fasted state
Trial: 32053101
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg daily for 8 days
Trial: 32053101
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg generic sofosbuvir after a high-fat meal
Trial: 32053101
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg generic sofosbuvir
Trial: 34781421
Drug: Dexmedetomidine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (2.0 μg/kg, i.m.) in 2.5 mL saline
Trial: 34781421
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo, i.m.) 2.5 mL
Trial: 32969758
Drug: Reldesemtiv 150
RxNorm normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reldesemtiv 150 mg bid
Trial: 32969758
Drug: Reldesemtiv 300
RxNorm normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reldesemtiv 300 mg bid
Trial: 32969758
Drug: Reldesemtiv 450
RxNorm normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reldesemtiv 450 mg bid
Trial: 34218726
Drug: All reldesemtiv
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All reldesemtiv doses combined
Trial: 35988059
Drug: Eldecalcitol capsule
RxNorm normalized name: Decalcitrol
DrugBank: Eldecalcitol (DB05295)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Eldecalcitol capsule (0.75 μg) under fasting conditions
Trial: 35988059
Drug: Eldecalcitol capsule
RxNorm normalized name: Decalcitrol
DrugBank: Eldecalcitol (DB05295)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Eldecalcitol capsule (0.75 μg) under fed conditions
Trial: 35988059
Drug: Eldecalcitol capsule
RxNorm normalized name: Decalcitrol
DrugBank: Eldecalcitol (DB05295)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Eldecalcitol capsule (0.75 μg)
Trial: 32538182
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing of vitamin D (28 IU/kg)
Trial: 32538182
Drug: Fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosing of vitamin D (2000 IU/day)
Trial: 32538182
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (weight-based and fixed dosing)
Trial: 32538182
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing of vitamin D
Trial: 36235651
Drug: Dual supplementation
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual supplementation of multi-strain probiotic (B. lactis Bi‐07, L. paracasei Lpc‐37, L. acidophilus NCFM, B. lactis Bl‐04) and omega-3 supplements for eight weeks
Trial: 36235651
Drug: Dual supplementation
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual supplementation of multi-strain probiotic and omega-3 supplements
Trial: 33121627
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg Simmental bull seminal plasma protein per mL egg yolk‐citrate extender (T1)
Trial: 33121627
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Simmental bull seminal plasma protein per mL egg yolk‐citrate extender (T2)
Trial: 32633896
Drug: Transcutaneous application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous application of gaseous CO2 (20 therapies with medical-grade CO2 gas)
Trial: 32633896
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same treatment with air)
Trial: 33478324
Drug: 1% iodiconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% iodiconazole cream (0.4 g)
Trial: 33478324
Drug: 2% iodiconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% iodiconazole cream (0.4 g)
Trial: 33478324
Drug: 4% iodiconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% iodiconazole cream (0.4 g)
Trial: 32505485
Drug: intermittent theta
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermittent theta burst protocols (iTBS) rTMS (50 Hz, 900 pulses, 20 daily sessions over 4 weeks)
Trial: 35439754
Drug: OPF‐105 (novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPF‐105 (novel all‐in‐one peripheral parenteral nutrition solution)
Trial: 35439754
Drug: BFL (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFL (combination of a commercially available PPN solution and fat emulsion)
Trial: 34628077
Drug: Psychosocial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychosocial intervention based on cognitive-behavioral therapy delivered by Medical Assistants in primary care.
Trial: 32705831
Drug: Celecoxib capsules
RxNorm normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib capsules (200 mg once daily)
Trial: 35268070
Drug: c‐NCS diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c‐NCS diet (50‐100 mg/day NCS)
Trial: 35268070
Drug: NCS‐f diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCS‐f diet (less than 10 mg/day NCS)
Trial: 33065120
Drug: CSL112 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 6 g
Trial: 32279349
Drug: Short-term patch
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term patch test protocol with an application period of 20 minutes
Trial: 32279349
Drug: Patch test
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch test results
Trial: 33350361
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Lactobacillus fermentum CECT5716 and Bifidobacterium breve CECT7263 (1×10^8 cfu/day per strain)
Trial: 33350361
Drug: Simethicone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone (80 mg/day)
Trial: 36267269
Drug: Dexmedetomidine postconditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine postconditioning (DPOC) via intravenous administration at 0.6 μg kg−1 for 10 min immediately after unclamping the renal artery
Trial: 36267269
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received saline administered under the same protocol as DPOC
Trial: 35467064
Drug: AMX‐CLG (1875/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMX‐CLG (1875/125 mg of AMX‐CL orally 1–2 h prior to surgery)
Trial: 35467064
Drug: AMXG (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMXG (2 g of amoxicillin orally)
Trial: 33087119
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg every 4 weeks (Q4W)
Trial: 33469316
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg Q4W
Trial: 32705817
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with vigabatrin (80–150 mg/kg/day)
Trial: 32705817
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment of epileptic seizures
Trial: 34799110
Drug: Altered crude
RxNorm normalized name: COAL TAR,CRUDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Altered crude protein (CP) content in dietary supplements (15.3% during baseline, 19.3% during experimental)
Trial: 34799110
Drug: Regular supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular supplements (13.5% during baseline, 14.8% during experimental)
Trial: 33973327
Drug: RNase1 pretreatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RNase1 pretreatment 24 hours before A. hydrophila injection
Trial: 34311528
Drug: EPP-AF® 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPP-AF® 400 mg/day
Trial: 34311528
Drug: EPP-AF® 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPP-AF® 800 mg/day
Trial: 35654363
Drug: Ranibizumab (0.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5-mg or 2.0-mg) administered monthly or pro re nata over 24 months
Trial: 32926835
Drug: Single-dose pneumococcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose pneumococcal conjugate vaccine
Trial: 32926835
Drug: Two-dose primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine
Trial: 35034025
Drug: L-FABP biomarker
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-FABP biomarker assay
Trial: 35034025
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no L-FABP)
Trial: 33038728
Drug: No bio-fertilizers
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bio-fertilizers (NF) with 200 mg kg−1 SDZ
Trial: 33038728
Drug: Co-application of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-application of bio-fertilizers and SDZ (100 and 200 mg kg−1)
Trial: 33038728
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg kg−1 SDZ with no bio-fertilizers